uploads///Bayer Outperformed Sanofi

Bayer Rose 2.1% as It Increased Investments in Cancer Drugs

By

Dec. 23 2015, Updated 3:04 p.m. ET

Top-performing stocks

On December 10, 2015, the stocks at the top of the SPDR Euro STOXX 50 ETF (FEZ) were Bayer, Deutsche Post, Airbus (EADSY), Daimler (DDAIF), Volkswagen (VLKAY), and SAP (SAP). They rose 2.1%, 1.6%, 1%, 0.92%, 0.87%, and 0.80%, respectively, that day.

Article continues below advertisement

Bayer pushed up FEZ with a gain of 2.1%

Bayer is a German-based pharmaceutical company. The company’s business is divided into three parts: Bayer Health Care, Bayer CropScience, and Bayer MaterialScience.

Key points on Bayer performance

  • Bayer announced that it’s accelerating its investments in more cancer drugs.
  • Bayer is on the way to achieve a bigger share of $100 billion global markets for cancer treatment.
  • Bayer said that it may have five cancer drugs on the market by 2020.
  • David Weinreich, who oversees development of Bayer’s cancer drugs, said, “We want to be a major oncology player.”

This news drove the stock, and it rose 2.1% on December 10. The above graph compares Bayer’s performance with its peer Sanofi since November 2015.

Article continues below advertisement

Bayer’s return

Bayer is currently trading at 114.5 euros. Its 52-week high is 146.5 euros, and its 52-week low is 106.8 euros. Bayer’s current price-to-earnings ratio is 25.95x. Its current price-to-book-value ratio is 4.2x.

Bayer’s year-to-date return is 13%. The quarter-to-date return is 0.27%. The Health Care Select Sector SPDR ETF (XLV) rose 0.75% on December 10.

Currently, the stock is trading at 5%, 3%, and 6% below its 100-day, 50-day, and 20-day moving averages, respectively.

Sanofi, a competitor for Bayer

Sanofi (SNY) is currently trading at 76.8 euros. It returned -0.66% on December 10, 2015. Its 52-week high is 101.1 euros, and its 52-week low is 69.8 euros.

Sanofi’s current price-to-earnings ratio is 20.69x. Its current price-to-book-value ratio is 1.77x. The year-to-date return is 14.5%. The quarter-to-date return is -9.5%.

Currently, the stock is trading at 13%, 10%, and 6% below its 100-day, 50-day, and 20-day moving averages, respectively.

In the next part of this series, we’ll analyze the performance of FEZ’s bottom stocks on December 10, 2015.

Advertisement

More From Market Realist